Dr. Michael Irwin Ebright, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 29 Hospital Plaza, Suite 505, Stamford, CT 06902 Phone: 203-276-4404 Fax: 203-276-4405 |
David Yuh, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 29 Hospital Plz Ste 501, Stamford, CT 06902 Phone: 203-276-4400 Fax: 203-276-4401 |
Dr. William C Feng, M.D., D.SC. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Not Enrolled in Medicare Practice Location: 32 Strawberry Hill Ct, Stamford, CT 06902 Phone: 203-276-4400 Fax: 203-276-4401 |
News Archive
Due to impending budget restrictions and health care restructuring, the Provincial Health Ethics Network (PHEN) of Alberta will develop a scaled-down structure and function to take effect April 1, 2010. While it is not yet clear what form a restructured PHEN will take, it is anticipated to be based on a primarily volunteer-driven resource base.
In the wake of the shooting rampage today in Tucson, Ariz., at an event held by Democratic Rep. Gabrielle Giffords, the House has postponed all legislative business for the next week. This most importantly includes the vote to repeal President Obama's health care law, which was scheduled for Wednesday and would have be the first major vote of the House since Republicans took control last week.
Mylan today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Nisoldipine Extended-release Tablets, 8.5 mg, 17 mg, 25.5 mg and 34 mg.
There is no doubt that America has the world's most skilled doctors and nurses and its finest hospitals. Every day, many Americans receive care that is as good as or better than any in the world. But far too often, we fall short of that high standard when good people get trapped in flawed systems (Kathleen Sebelius and Sue Currin, 6/10).
Samsung Biologics and Biogen Idec announced today that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December.
› Verified 1 days ago